These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22315053)

  • 1. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Kashiwagi S; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Jul; 41(7):3535-3542. PubMed ID: 34230149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
    Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
    Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
    Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
    Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
    Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
    Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
    Giampieri R; Puzzoni M; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Germano D; Zagonel V; Codecà C; Libertini M; Labianca R; Cascinu S; ; Scartozzi M
    Br J Cancer; 2017 Oct; 117(8):1099-1104. PubMed ID: 28926529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bevacizumab in the treatment of metastatic colorectal cancer.
    Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
    Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
    Moscetti L; Nelli F; Fabbri MA; Sperduti I; Alesini D; Cortesi E; Gemma D; Gamucci T; Grande R; Pavese I; Franco D; Ruggeri EM
    Invest New Drugs; 2013 Aug; 31(4):1035-43. PubMed ID: 23417697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
    Scartozzi M; Galizia E; Chiorrini S; Giampieri R; Berardi R; Pierantoni C; Cascinu S
    Ann Oncol; 2009 Feb; 20(2):227-30. PubMed ID: 18842611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
    Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
    Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results.
    Hofheinz R; Petersen V; Kindler M; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Stein A; Hinke A; Arnold D
    BMC Cancer; 2014 Oct; 14():761. PubMed ID: 25311943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.